



SEMPERIT GROUP Q1-3 2020 / Q3 2020 INVESTOR PRESENTATION

Dr Martin Füllenbach, CEO

Gabriele Schalleger, CFO

19 November 2020



Agenda

Key Highlights and Executive Summary (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)

Leadership priorities and action plan 2020 (p.21)

Appendix (p.24)



Key Highlights Q1-3'20: corona and restructuring setting the agenda



- **Successful restructuring:** Material impact from transformation and restructuring process
 - **Industrial Sector:** resilient margins against the backdrop of global recession and different speed of recovery
 - **Medical Sector:** higher operational performance and increased efficiency underpin positive corona impact
- **Corona pandemic:**
 - Impact on **Industrial Sector** but less severe than anticipated given lean operational structure and ongoing efficiency enhancement
 - **Medical Sector** benefits from high demand and exceptional market prices but growing competitive landscape
- **Completion of transformation process accelerated** and supported by strict and additional cost measures



- **Revenue up by +0.8% to € 657.2m**
 - Impact of ongoing economic slowdown
 - Key driver: significantly higher Sempermed production volumes and market prices
- **EBITDA at € 118.5m, +96.1% vs. Q1-3'19**
Operational improvement at Sempermed offsets top-line pressure at Industry
- **Adjusted EBIT at € 92.6m** more than tripled vs. Q1-3 2019
EBIT affected by **reversal of Sempermed impairment** and **Sempertrans impairment** (amounting to € +86.7m and € -19.9m respectively in Q1-3'20)
- **Net profit at € 137.3m** vs. € -34.1m in Q1-3'19; **operational net profit at € 62.2m** vs last year's €8.6m
- **Positive Free Cash Flow further improved to € +98.8m** vs. € 60.2m in Q1-3'19
- **Capex at € 17.4m in Q1-3'20** (€ 25.1m in Q1-3'19)
- **Repayment of the hybrid capital** planned within the next six months



Corona impact stress tested and accelerated restructuring process

Health & Safety	<ul style="list-style-type: none"> • Number of people who had tested positive so far rose to 117 in total by now • Approximately 20% of all suspected and positive cases occurred during the last four weeks • Production continued smoothly, with special management attention at clusters in Belchatow (PL) and Odry (CZ) 	
Supply	Medical Sector <ul style="list-style-type: none"> • Finished goods supply for exam gloves had to be replaced due to partially overheated market • High market demand for nitrile-latex and natural latex – while capacities are limited 	Industrial Sector <ul style="list-style-type: none"> • Prices for many raw have increased lately on the back of high demand and limited availability
Market	<ul style="list-style-type: none"> • Very high global demand for hygienic equipment • Market prices have further increased • End of exuberant price rally not yet foreseeable 	<ul style="list-style-type: none"> • Industrial segments face lower demand and reduced order books with market recovery at a different speed • Changing customer sentiment leads to uncertain project planning and budgeting • Impact of second wave remains unclear
Restructuring & Counter-measures	<ul style="list-style-type: none"> • Turnaround of operational efficiency supports currently high demand • Restructuring effort less of temporary but more long-term nature • Minimal use of government support 	
Outlook	<ul style="list-style-type: none"> • FY 2020 EBIT forecast further increased due to upside from restructuring and continuing demand for medical products • Impact of corona vaccine not expected earlier than next nine months, full order book for Sempermed in 2021 • More general change of customer behaviour towards more hygiene added new clients 	



Update on Industrial strategy implementation



Focus on industrial rubber strategy

in implementation

Establishing growth platform, organically and inorganically



Separation from the medical segment

postponed

Planned to be actively pursued after summer 2021



Higher market and customer orientation

accelerated

Strong customer focus during corona pandemic



Organic growth

slowed down

Lower slowdown against original expectation but market recovery will take longer



Geographic expansion

in implementation

Economic recovery in the US supports expansion through new regional hub



Agenda

Key Highlights and Executive Summary (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)


Leadership priorities and action plan 2020 (p.21)

Appendix (p.24)



Successful restructuring supported by positive corona effect

- Ongoing exceptional performance of Medical Sector both at top line and profitability
- Industrial Sector: top line under pressure – margins remain resilient
- Operational Group EBITDA yoy improvement for 11th consecutive quarter



- **Revenue +0.8%**
 - Medical Sector at € 288.2m, up by +27.5%
 - Industrial Sector at € 369.0m, down by -13.4%
- **EBITDA at € 118.5m, +96.1%**
- **EBIT at € 159.5m, >100%**
 - positive impact on reported EBIT due to reversal in Q2'20 of Sempermed impairment
 - At operational level: Adjusted EBIT more than tripled yoy

1) Q1-3'19: adjusted for one-off effect due to release of provision in Sempermed for Brazilian court case for tax liabilities (€ 4m)


Q1-3'18: adjusted for one-off effect of € 4m from closure of Sempertrans site in China.

Q1-3'17: adjusted for one-off effects from JV transaction of € 85m and one-off effects from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m) and expenses resulting from tax audit in Austria (€ 5m)



Industrial Sector EBITDA Q3'2020

Strong and resilient margins on the back of restructuring and efficiency enhancement




¹⁾ Q2'18 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.




Semperflex Q1-3 2020

Robust EBITDA margin – above Q3'19 level

Semperflex



Q1-3 2020 vs. Q1-3 2019



- Revenue down due to reduced market demand further to the corona pandemic impact in Q1-3'20 and the global economic downturn since Q1-3'19
- Size of order book decreased yoy
- Price pressure increasing lately
- EBITDA in Q1-3'20 below Q1-3'19 (-11.4%)
- The successful market launch of high-end hoses for OEM prewarming units and also supply share wins, especially in North America







Sempertrans Q1-3 2020

More severe pressure on the business

Sempertrans



Q1-3 2020 vs. Q1-3 2019



- Global mining companies reduced capex significantly after the corona outbreak – corresponding impact on the business
- Impairment²⁾ in H1'20 triggered by consistently negative market impact from corona burdens reported EBIT
- Operational EBIT²⁾ at €5.8m vs. €9.2m in Q1-3'19
- Falling demand reflected in reduced order book, notably lower order intake in Q2-Q3'20



1) Q1'19 Revenue and EBITDA: positive effects of € 1.3m profit from sale of assets of closed factory in China



2) Impairment requirement recognised at the end of the second quarter, now amounting to EUR 19.9 million based on the foreign exchange average rates for Q1-3'20




Semperseal Q1-3 2020

Active focus keeps margins above last year's level


Semperseal



Q1-3 2020 vs. Q1-3 2019



- Top line pressure due to reduced market demand – construction industry first impacted by corona outbreak but now in recovery
- While EBITDA decreased by 4.7% yoy, EBITDA margin at 13.1% even exceeded last year as a consequence of the transformation process
- Order book above Q3'19 due to better customer intimacy, with strong customer feedback on our supply chain of full product range
- Smaller workshop in CZ to be closed as part of the restructuring program





Split of former Semperform into Semperseal and Semperform as of 1st January 2020



Semperform Q1-3 2020


Sustainably high margins – exceeding 2019 level

Semperform




Q1-3 2020 vs. Q1-3 2019

Semperform



- Revenue down yoy (-10.2%) due to reduced economic activity starting in late 2019 as well as the corona impact corona impact, e.g. ski lifts closed at early stage, automotive plant shutdowns in Q2, filtration industry (e.g. beer) reduced, railway tenders delayed
- Q1-3'20 EBITDA down by 3.6% but margin improved by 1.4PP yoy
- Order book down – but slow recovery, e.g. hand rails in China household appliances, piping gaskets
- High operational performance in China



Split of former Semperform into Semperseal and Semperform as of 1st January 2020 – historic Semperform numbers adapted accordingly




Medical Sector / Sempermed segment Q1-3 2020

EBITDA margin boosted by market dynamics, leveraged by operational efficiency

Medical Sector

Sempermed



Q1-3 2020 vs. Q1-3 2019

Revenue current period	288
Revenue comparable period	226
EBITDA current period	67
EBITDA comparable period	6

in € m

- Ongoing top-line growth driven by high demand and increasing market prices on the back of very high production output²⁾
- Thanks to restructuring efforts, production now at highly competitive level, full capacity and top quality
- EBITDA and margins improved due to significantly higher operational efficiencies, with market prices substantially above pre-corona levels
- Order book increased to historically high level – both examination and surgical glove capacity for 2021 completely booked out



1) Q3'19 EBITDA adjusted for € 4m due to release of provision in Sempermed for Brazilian court case for tax liabilities

2) Reversal of impairment requirement recognised at the end of the second quarter, now amounting to EUR 86.7 million based on the foreign exchange average rates for Q1-3'20



Agenda

Key Highlights and Executive Summary (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)


Leadership priorities and action plan 2020 (p.21)

Appendix (p.24)



Revenue development

in € m




¹⁾ Semperform has been split into Semperséal and Semperform as of 1 Jan 2020
Change of each segment / sector for Q1-3'20 vs Q1-3'19.



Corona impact on reported EBITDA: Medical Sector strong – Industrial Sector resilient

Margin strength against the corona impact

in € m



	Q1-3'19	Semperséal	Semperform	Sempermed	Corporate	Q1-3'20
EBITDA Q1-3'19	60.4m	39.3m	10.8m	5.6m	-19.8m	
EBITDA Q1-3'20		34.8m	12.4m	67.3m	-14.1m	118.5m
EBITDA margin Q1-3'20	9.3%	24.0%	20.0%	23.4%	–	18.0%

Change of intercompany consolidation included in Corporate



Financials and profitability overview

in € m	Q1-3 2020 ²⁾	Change	Q1-3 2019 ³⁾	Q3 2020 ⁴⁾	Change	Q3 2019 ⁵⁾
Revenue	657.2	+0.8%	652.2	238.2	+10.8%	214.9
EBITDA adjusted	118.5	>100%	56.4	60.9	>100%	17.3
EBITDA margin adjusted	18.0%	+9.4 PP	8.6%	25.6%	+17.6 PP	8.0%
EBITDA	118.5	+96.1%	60.4	60.9	>100%	21.3
EBITDA margin	18.0%	+8.8 PP	9.3%	25.6%	+15.7 PP	9.9%
EBIT adjusted	92.6	>100%	29.0	49.2	>100%	8.1
EBIT margin adjusted	14.1%	+9.7 PP	4.4%	20.7%	+16.9 PP	3.8%
EBIT	159.5	>100%	-13.7	47.2	>100%	-34.6
EBIT margin	24.3%	+26.4 PP	-2.1%	19.8%	+35.9 PP	-16.1%
Earnings after tax adjusted	62.6	>100%	8.6	38.7	>100%	2.6
Earnings after tax	137.3	>100%	-34.1	35.6	>100%	-39.9
Earnings per share (EPS)¹⁾, in EUR	6.38	>100%	-1.89	1.65	>100%	-2.00

¹⁾ Attributable to the shareholders of Semperit AG Holding from ordinary shares, excluding interest from hybrid capital

²⁾ Q1-3 2020: adjusted for the positive special effect from the write-up in the Sempermed segment (EBIT effect: +86.7 million EUR; earnings after tax effect: +91.9 million EUR) and for the negative special effect of the impairment in the segment Sempertrans (EBIT effect EUR –19.9 million; earnings after tax effect: EUR –16.2 million)

³⁾ Q1-3 2019: adjusted on the one hand for the positive one-off effect from the reversal of the provision for the tax proceedings on transaction taxes in Brazil (Q1-3'19 EBITDA, EBIT, earnings after tax effect: +4.0 million EUR, on the other hand adjusted for the negative special effect of the impairment in the Sempermed segment (Q1-3'19 EBIT and earnings after tax effect: –46.8 million EUR)

⁴⁾ Q3 2020: adjusted for the positive special effect from the write-up in the Sempermed segment (EBIT: EUR –2.1 million; earnings after tax effect: EUR –2.0 million) and the negative special effect from the impairment in the Sempertrans segment (EBIT and earnings after tax effect EUR +0.1 million)


⁵⁾ Q3 2019: adjusted on the one hand for the positive one-off effect from the reversal of the provision for the tax proceedings on transaction taxes in Brazil (Q3'19 EBITDA, EBIT and earnings after tax effect: +4.0 million EUR), on the other hand adjusted for the negative special effect of the impairment in the Sempermed segment (Q3'19 EBIT and earnings after tax effect: –46.8 million EUR)



Working Capital overview

Components of Working Capital

in € m



¹⁾ Trade Working Capital in % of LTM revenues




Free cash flow development and CAPEX

Cash Flow Development

- Improved results, active WC management and strict CAPEX control
- Q1-3'20 FCF increased yoy by 64%

CAPEX

- Q1-3'20 CAPEX at €17.4m – main focus on maintenance
- FY 2020 CAPEX to remain below € 40m



¹⁾ Cash flow calculation methodology change as of end of 2018, Q1-3 2017 and Q1-3 2018 adjusted accordingly: "interest received" is now shown under cash flow from investing activities instead of operating activities, "interest paid" is now included in cash flow from financing activities instead of operating activities.


²⁾ Q1-3 2017 investment cash flow adjusted by € 160m (Joint Venture Termination)



Balance sheet structure and financial profile

Balance sheet structure

Balance sheet 30/9/2020: € 773m
Balance sheet 31/12/2019: € 702m



Financial profile as of 30 September 2020

- **Cash and cash equivalents** of € 157m
- Financial liabilities:
 - **Corporate Schuldschein loan partially repaid** in Q1'20 and Q3'20, currently at € 169m
 - Liabilities to banks at € 1m
- **Newly agreed more flexible undrawn Credit Facility of € 75m** to secure liquidity
- **Net debt further reduced** to € 12.7m
 - Down by € 60.8m since end of Dec. 2019
 - Net debt / EBITDA of 0.1x, compared to 1.1x as of end of Dec. 2019
- Equity ratio of 47.4% vs. 39.0% in Dec. 2019
- **Further strengthening the financial profile**
 - **Hybrid capital:** remaining undrawn € 20m line cancelled in July; repayment of a small tranche of € 20m in Q3'20; **complete repayment planned** within the next six months
 - **OeKB** line (€ 15m) secured in August with favourable conditions



Agenda

Key Highlights and Executive Summary (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)

Leadership priorities and action plan 2020 (p.21)

Appendix (p.24)



Outlook 2020 upgraded

Medical Sector

- Strong focus on business execution
- Separation will follow clear strategic rationale (market prices, order book, general market environment)
- Corona price premium to continue into 2021

Industrial Sector

- Different pace of recovery is expected – depending on severity of second wave of corona pandemic
 - Semperflex: slow market recovery expected
 - Sempertrans: only short-term visibility
 - Semperseal: supported by recovery in construction industry
 - Semperform: mixed developments with short-term visibility

Outlook 2020: EBITDA to reach €200-225m, and EBIT €230-255m;
Strong momentum to continue into 2021

Evaluation of new industrial identity
balanced approach on organic and inorganic growth



Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Modecenterstrasse 22

1031 Vienna, Austria

Financial Calendar 2021

18.03.2021	Publication of 2020 annual financial statements
27.04.2021	Annual general meeting, Vienna
03.05.2021	Dividend payment day
19.05.2021	Report on Q1 2021
19.08.2021	Half-year financial report 2021
17.11.2021	Report on Q1-3 2021

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Key Highlights and Executive Summary (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)

Leadership priorities and action plan (p.21)

Appendix (p.24)



Sectors and Group: Q1-3 2020 vs Q1-3 2019¹⁾

in EUR m	Industrial Sector			Medical Sector			Semperit Group		
	Q1-3 2020	Q1-3 2019	%	Q1-3 2020	Q1-3 2019	%	Q1-3 2020	Q1-3 2019	%
Revenue	369.0	426.2	-13.4%	288.2	226.0	27.5%	657.2	652.2	+0.8%
EBITDA	65.3	74.7	-12.6%	67.3	5.6	>100%	118.5	60.4	+96.1%
EBITDA margin	17.7%	17.5%	+0.2 PP	23.4%	2.5%	+20.9 PP	18.0%	9.3%	+8.8 PP
Adj. EBITDA	65.3	74.7	-12.6%	67.3	1.5	>100%	118.5	56.4	+47.2%
Adj. EBITDA margin	17.7%	17.5%	+0.2 PP	23.4%	0.7%	+22.7 PP	18.0%	8.6%	+4.8 PP
EBIT	26.9	55.0	-51.1%	147.5	-47.2	>100%	159.5	-13.7	>100%
EBIT margin	7.3%	12.9%	-5.6 PP	51.2%	-20.9%	+72.1 PP	24.3%	-2.1%	+26.4 PP
Adj. EBIT	46.8	55.0	-14.9%	60.7	-4.5	>100%	92.6	29.0	>100%
Adj. EBIT margin	12.7%	12.9%	-0.2 PP	21.1%	-2.0%	+23.1 PP	14.1%	4.4%	+9.7 PP
Earnings after tax	–	–	–	–	–	–	137.3	-34.1	>100%
Adj. Earnings after tax	–	–	–	–	–	–	62.6	8.6	>100%
Earnings per share in EUR	–	–	–	–	–	–	6.38	-1.89	>100%
Additions in tangible and intangible assets	12.6	16.5	-24.0%	3.1	4.6	-32.7%	16.0	21.4	-25.0%
Employees	3,474	3,705	-6.2%	3,311	3,263	+1.5%	6,921	7,101	-2.5%

¹⁾ Q1-3 2020: adjusted for the positive special effect from the write-up in the Sempermed segment (EBIT effect: +86.7 million EUR; earnings after tax effect: +91.9 million EUR) and for the negative special effect of the impairment in the segment Sempertrans (EBIT effect EUR –19.9 million; earnings after tax effect: EUR –16.2 million)


Q1-3 2019: adjusted on the one hand for the positive one-off effect from the reversal of the provision for the tax proceedings on transaction taxes in Brazil (Q1-3'19 EBITDA, EBIT, earnings after tax effect: +4.0 million EUR; on the other hand adjusted for the negative special effect of the impairment in the Sempermed segment (Q1-3'19 EBIT and earnings after tax effect: –46.8 million EUR)




Semperit Group adj. where applicable

Semperit Group adj. where applicable																		
in EUR m	Q1 2017 adj. ¹⁾	Q2 2017 adj. ¹⁾	Q3 2017 adj. ¹⁾	Q4 2017 adj. ¹⁾	FY 2017 adj. ¹⁾	Q1 2018	Q2 2018 adj. ²⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. ³⁾	Q4 2019 adj. ⁴⁾	FY 2019	Q1 2020	Q2 2020 adj. ⁵⁾	Q3 2020 adj. ⁶⁾
Revenue	229.3	232.3	208.4	204.2	874.2	220.9	227.6	221.7	208.2	878.5	212.9	224.4	214.9	188.3	840.6	199.1	219.8	238.2
EBITDA	9.6	12.9	10.4	2.9	35.8	15.8	17.0	13.1	4.5	50.3	16.5	22.7	17.3	7.4	63.8	16.9	40.7	60.9
EBITDA margin	4.2%	5.6%	5.0%	1.4%	4.1%	7.1%	7.5%	5.9%	2.2%	5.7%	7.7%	10.1%	8.0%	3.9%	7.6%	8.5%	18.5%	25.6%
EBIT	1.6	4.6	1.7	-8.7	-0.8	6.0	7.2	4.3	-2.2	15.4	7.8	13.1	8.1	-0.8	28.2	9.8	33.6	49.2
EBIT margin	0.7%	2.0%	0.8%	-4.3%	-0.1%	2.7%	3.2%	1.9%	-1.0%	1.7%	3.7%	5.8%	3.8%	-0.4%	3.4%	4.9%	15.3%	20.7%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Q1 2017 adj. for positive one-off effects from JV transaction of € 85m. Figures for Q2, Q3 and Q4 2017 restructuring expenses/closure in France (€ 11m) and valuation adjustment in IT (€ 4m EBITDA), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ²⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA). ³⁾ Q3 2019 adjusted for negative one-off effect of € 47m from impairment of Sempermed (adj. for EBIT) and € 4m (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities. ⁴⁾ Q4 2019: impairment figure of Q3 2019 stepped up by € 2m due to additions to assets and FY deviations ⁵⁾ Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect -20.0 Million EUR) ⁶⁾ Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR -2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million).



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)																		
	Q1 2017 adj. ¹⁾	Q2 2017 adj. ¹⁾	Q3 2017 adj. ¹⁾	Q4 2017 adj. ¹⁾	FY 2017 adj. ¹⁾	Q1 2018	Q2 2018	Q3 2018 adj. ²⁾	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020
in EUR m																		
Revenue	53.5	53.2	46.8	52.5	206.1	58.8	62.8	53.4	55.1	230.0	61.1	59.7	53.8	48.0	222.7	46.8	51.5	46.6
EBITDA	11.7	10.5	8.7	10.5	41.4	13.7	14.9	9.3	10.9	48.9	13.9	14.5	10.8	8.7	47.9	9.3	14.0	11.4
EBITDA margin	21.8%	19.8%	18.6%	19.9%	20.1%	23.4%	23.8%	17.4%	19.8%	21.3%	22.8%	24.3%	20.1%	18.1%	21.5%	19.9%	27.2%	24.5%
EBIT	9.6	8.6	6.8	7.8	32.7	11.1	12.3	6.9	8.1	38.4	11.1	11.5	7.7	5.7	36.0	6.5	11.2	8.7
EBIT margin	18.0%	16.1%	14.5%	14.8%	15.9%	18.9%	19.7%	12.9%	14.8%	16.7%	18.2%	19.2%	14.3%	11.9%	16.2%	13.9%	21.8%	18.6%

Sempertrans (Conveyor belts)																		
	Q1 2017 adj. ¹⁾	Q2 2017 adj. ¹⁾	Q3 2017 adj. ¹⁾	Q4 2017 adj. ¹⁾	FY 2017 adj. ¹⁾	Q1 2018	Q2 2018 adj. ²⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾
in EUR m																		
Revenue	41.3	36.8	35.7	32.1	146.0	34.6	37.0	37.6	35.5	144.8	30.4	37.8	35.1	30.6	134.0	29.5	32.5	28.4
EBITDA	0.6	-2.4	-1.4	-2.1	-5.3	0.5	0.8	2.4	0.7	4.4	2.7	5.4	4.6	0.8	13.5	1.6	5.0	2.1
EBITDA margin	1.4%	-6.4%	-3.9%	-6.6%	-3.6%	1.4%	2.1%	6.4%	2.1%	3.0%	9.0%	14.2%	13.1%	2.5%	10.1%	5.4%	15.4%	7.6%
EBIT	-0.3	-3.3	-2.2	-3.0	-8.9	-0.4	-0.1	1.6	-0.4	0.7	1.8	3.8	3.6	-0.3	8.9	0.6	3.9	1.4
EBIT margin	-0.8%	-8.9%	-6.3%	-9.6%	-6.1%	-1.1%	-0.2%	4.3%	-1.1%	0.5%	6.0%	10.0%	10.4%	-0.9%	6.7%	1.9%	11.9%	5.0%

¹⁾ Q1 2017 adj. for positive one-off effects from JV transaction of EUR 85 million. Figures for Q2, Q3 and Q4 2017 restructuring expenses/closure in France (EUR 11 million) and valuation adjustment in IT (EUR 4 million EBITDA), expenses resulting from tax audit in Austria (EUR 5 million, mainly for refund of energy supply charge).

²⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (EUR 4 million for EBITDA).

³⁾ Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempermed segment (EBIT effect: EUR 20.0 million).

⁴⁾ Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment EBIT effect: EUR +0.1 million



Semperform and Semperseal (adj. where applicable)

Semperform (Window and door profiles, Handrails) - before 2020

in EUR m	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020
Revenue	47.5	50.7	50.3	43.7	192.2	49.9	50.5	47.8	42.4	190.6			
EBITDA	4.5	7.3	6.2	3.9	21.9	7.9	8.3	6.6	3.3	26.0			
EBITDA margin	9.6%	14.4%	12.2%	8.9%	11.4%	15.7%	16.4%	13.8%	7.8%	13.6%			
EBIT	2.4	5.1	4.2	1.5	13.2	5.4	5.9	4.2	0.5	16.0			
EBIT margin	5.0%	10.1%	8.4%	3.4%	6.9%	10.9%	11.6%	8.7%	1.1%	8.4%			

Semperform (Window and door profiles, Handrails) - after 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020
Revenue	22.4	24.6	22.3	21.8	91.1	19.9	21.9	20.4
EBITDA	4.0	4.8	4.1	2.7	15.6	3.5	5.0	4.0
EBITDA margin	17.7%	19.6%	18.4%	12.2%	17.1%	17.5%	22.6%	19.6%
EBIT	3.1	4.0	3.2	1.7	12.0	2.6	4.1	3.1
EBIT margin	13.9%	16.1%	14.3%	7.7%	13.1%	12.9%	18.5%	15.1%

Sempersal (Profiles and Rubber Sheeting) starting in 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020
Revenue	27.5	25.8	25.6	20.5	99.5	25.4	21.7	24.4
EBITDA	3.9	3.4	2.5	0.6	10.4	3.3	3.2	2.9
EBITDA margin	14.1%	13.2%	9.8%	3.0%	10.5%	12.8%	14.7%	12.0%
EBIT	2.3	1.9	1.0	-1.2	4.0	1.8	1.7	1.4
EBIT margin	8.4%	7.3%	3.9%	-5.8%	4.0%	6.9%	8.0%	5.8%



Sempermed (adj. where applicable)

Sempermed (Gloves)																		
	Q1 2017 adj. ²⁾	Q2 2017 adj. ²⁾	Q3 2017 adj. ¹⁾	Q4 2017	FY 2017 adj. ¹⁾²⁾	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. ³⁾	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. ⁴⁾	Q3 2020 adj. ⁵⁾
in EUR m																		
Revenue	89.2	92.2	78.8	76.9	337.1	80.0	77.1	80.4	73.9	311.5	71.5	76.4	78.2	67.3	293.3	77.5	92.2	118.4
EBITDA	0.0	1.7	1.6	-1.5	1.8	1.4	-1.3	-0.9	-3.1	-3.9	-0.9	0.6	1.8	-0.1	1.4	4.8	18.2	44.4
EBITDA margin	±0.0%	1.9%	2.0%	-2.0%	0.5%	1.8%	-1.7%	-1.1%	-4.2%	-1.3%	-1.2%	0.8%	2.3%	-0.1%	0.5%	6.1%	19.7%	37.5%
EBIT	-2.8	-1.2	-1.5	-6.7	-12.1	-2.2	-5.1	-3.9	-3.1	-14.3	-2.8	-1.4	-0.3	-0.9	-5.5	4.4	17.6	38.9
EBIT margin	-3.1%	-1.3%	-1.8%	-8.6%	-3.6%	-2.8%	-6.6%	-4.8%	-4.2%	-4.6%	-3.9%	-1.9%	-0.4%	-1.4%	-1.9%	5.5%	19.1%	32.8%

¹⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (EUR 2 million for Semperform, EUR 2 million for Sempermed)

²⁾ Q3 2017 Sempermed adj. for positive one-off effects from JV transaction of EUR 78 million for EBITDA.

³⁾ Q3 2019 adjusted for negative one-off effect of EUR 46.8 million from impairment of Sempermed (adj. for EBIT) and EUR 4 million (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

⁴⁾ Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

⁵⁾ Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)



Key figures 2009-2019

Key performance figures											
in EUR m	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016 adj. ⁴⁾	2017 adj. ⁵⁾	2018 adj. ⁶⁾	2019 adj. ⁷⁾
Revenue	588.1	689.4	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6
EBITDA	102.8	112.3	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8
EBITDA margin	17.5%	16.3%	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%
EBIT	69.6	82.3	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2
EBIT margin	11.8%	11.9%	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.4%
Earnings after tax	38.8	45.4	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2
EPS²⁾, in EUR	1.89	2.21	2.52	2.25	2.65	1.85	2.26	0.74	-2.13	-1.07	-0.33
Gross cash flow	92.6	91.0	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.7
Return on equity	12.5%	12.9%	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%

Balance sheet key figures											
in EUR m	2009	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016	2017	2018	2019
Balance sheet total	531.5	593.5	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8
Equity²⁾	310.6	351.1	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	273.4
Equity ratio	58.4%	59.2%	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%
Investments in tangible and intangible assets	22.7	52.5	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.4
Employees, at balance sheet date, FTEs	6,649	7,019	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902

¹⁾ 2011 restated (see Annual Report 2012, Notes 2.18), 2010 not restated.

²⁾ Attributable to shareholders of Semperit AG Holding from ordinary shares, excluding interest from hybrid capital.

³⁾ 2014 and 2015 restated.

⁴⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil.

⁵⁾ 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge).

⁶⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only).


⁷⁾ FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT)



CAPEX by quarter

CAPEX per segment


in € m





Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0




Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material¹⁾ used in industrial segments

Price index LFO-F-NWE



Price index wire rod



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment overview, FY 2019

Semperit Group

Group	Industrial Sector			Medical Sector	
	Semperflex	Sempertrans	Semperform ⁴⁾	Sempermed	
Revenue	€ 841m	€ 223m / 26% ¹⁾	€ 134m / 16% ¹⁾	€ 191m / 23% ¹⁾	€ 293m / 35% ¹⁾
EBITDA adj.	€ 64m ²⁾	€ 48m	€ 14m	€ 26m	€ 1m
Employees	6,902 ²⁾	1,672 / 27% ³⁾	939 / 13% ³⁾	990 / 15% ³⁾	3,165 / 44% ³⁾

Products and market position


Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe



Conveyor belts

One of the leading providers for heavyduty steel and textile cord belts



Profiles / Handrails

Leading position in construction (**profiles, piping, gaskets**) and infrastructure (**handrails, sheave liners, rail track**) business with European focus



Examination gloves

Among the top 10 glovemakers in the world



Surgical gloves

Leading position in Europe



¹⁾ Revenue in % of Group revenue.

²⁾ Group figure includes corporate center of € -25m, 136 employees.

³⁾ Employees in % of Group employees.


⁴⁾ The business units Profiles and Rubber

Sheeting were separated from the Semperform segment and are operated as individual segments under the name Semperseal as of 1 January 2020.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C